FMR LLC Discloses 5.44% Passive Stake in Immunovant (IMVT)
Ticker: IMVT · Form: SC 13G · Filed: Feb 9, 2024 · CIK: 1764013
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**FMR LLC just revealed a 5.44% stake in Immunovant, a bullish signal for the biotech stock.**
AI Summary
FMR LLC, a major investment management firm, and its Chair and CEO, Abigail P. Johnson, have disclosed a significant passive stake in Immunovant, Inc. (IMVT). As of December 31, 2023, FMR LLC beneficially owns 7,875,822 shares of Immunovant's common stock, representing 5.444% of the company's outstanding shares. This filing indicates FMR LLC's belief in Immunovant's long-term potential, signaling a vote of confidence for current and prospective investors in the biotech company.
Why It Matters
This filing shows a major institutional investor, FMR LLC, has taken a substantial position in Immunovant, which can be seen as a positive signal for the company's future prospects and may attract further investor interest.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by signaling confidence in the company.
Analyst Insight
A smart investor would view this as a positive signal, potentially researching Immunovant's fundamentals and future prospects more deeply, as a major institutional investor like FMR LLC has taken a significant stake.
Key Numbers
- 7,875,822 — Shares Beneficially Owned (Total shares of Immunovant common stock owned by FMR LLC and Abigail P. Johnson.)
- 5.444% — Percent of Class (The percentage of Immunovant's common stock outstanding that FMR LLC and Abigail P. Johnson collectively own.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Immunovant, Inc. (company) — subject company (issuer)
- Abigail P. Johnson (person) — reporting person, associated with FMR LLC
- 7,875,822 (dollar_amount) — shares beneficially owned by FMR LLC and Abigail P. Johnson
- 5.444% (dollar_amount) — percentage of class owned by FMR LLC and Abigail P. Johnson
Forward-Looking Statements
- Immunovant's stock price may experience increased stability or upward pressure due to institutional confidence. (Immunovant, Inc.) — medium confidence, target: 6-12 months
FAQ
Who is the primary entity reporting this ownership stake in Immunovant, Inc.?
The primary entity reporting this ownership stake is FMR LLC, a parent holding company, as stated in Item 1 and Item 3 of the filing.
What is the total number of shares of Immunovant, Inc. common stock beneficially owned by FMR LLC and Abigail P. Johnson?
FMR LLC and Abigail P. Johnson each beneficially own 7,875,822 shares of Immunovant, Inc. common stock, as indicated in Item 7 and Item 4(a) of the filing.
What percentage of Immunovant, Inc.'s common stock does FMR LLC and Abigail P. Johnson collectively own?
FMR LLC and Abigail P. Johnson collectively own 5.444% of Immunovant, Inc.'s common stock, as stated in Item 11 and Item 4(b) of the filing.
Under which SEC rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as indicated by the checked box in the filing and Item 3.
What is the CUSIP number for Immunovant, Inc. common stock?
The CUSIP number for Immunovant, Inc. common stock is 45258J102, as listed under 'Cusip #45258J102' and Item 2(e) in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Immunovant, Inc. (IMVT).